Loading clinical trials...

The Role of Electroencephalography in Caffeine Discontinuation Timing in Premature Infants | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

The Role of Electroencephalography in Caffeine Discontinuation Timing in Premature Infants

The Role of Electroencephalography Evaluation in Caffeine Discontinuation Timing in Premature Infants

NCT07324941•Uludag University

View on ClinicalTrials.gov

Summary

The aim of this observational study is to investigate whether functional maturation assessment by electroencephalography in preterm infants can provide reliable data for the safe discontinuation of caffeine therapy without recurrence of apnea. In preterm infants receiving caffeine therapy, an assessment of maturation will be performed by EEG at the time when discontinuation of caffeine treatment is planned.

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Infants born before 28 weeks of gestation with a birth weight of 1250 grams or less, who received prophylactic caffeine therapy.
•2. Infants with a birth weight greater than 1250 grams and a gestational age below 32 weeks, who required invasive mechanical ventilation and were started on prophylactic caffeine therapy.
•3. Infants born at less than 37 weeks of gestation, admitted to the neonatal intensive care unit, and treated with caffeine for apnea of prematurity.
•4. Infants whose parents or legal guardians provided informed consent.

Exclusion Criteria

•1. Infants who did not receive caffeine therapy,
•2. Infants for whom an EEG could not be performed,
•3. Infants with major congenital malformations such as neuromuscular disorders, central nervous system developmental abnormalities, thoracic malformations, or major cardiac anomalies,
•4. Infants who were transferred to another facility within one week before or after discontinuation of caffeine therapy.

Locations (1)

Division of Neonatology, Department of Pediatrics, Bursa Uludağ University Faculty of Medicine

Bursa, Turkey (Türkiye)

Key Dates

Start Date

January 2, 2026

Primary Completion Date

January 2, 2027

Completion Date

January 2, 2027

Last Updated

January 8, 2026

Enrollment

100

ESTIMATED participants

Conditions

Apnea NeonatalApnea of Prematurity

Contacts

Salih Çağrı Çakır

CONTACT

+90 533 3453739 salihcagri@uludag.edu.tr

"Prapela® SVS Incubator Pad for Apnea of Prematurity

NCT06374147

Apnea of Prematurity

View study

NOT_YET_RECRUITINGPHASE4

Caffeine Citrate in Preterm Infants at Risk of Apnea in Zambia

NCT06518603

Premature Infant DiseaseApnea of Prematurity+1 more

View study

NOT_YET_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Role of Electroencephalography in Caffeine Discontinuation Timing in Premature Infants

Inclusion Criteria

Exclusion Criteria

"Prapela® SVS Incubator Pad for Apnea of Prematurity

Caffeine Citrate in Preterm Infants at Risk of Apnea in Zambia

The Effect of Caffeine Therapy in Cardiovascular Stability in Preterm Neonates at Assiut University Children Hospital NICU

Arterial Oxygen Saturation on Ventilatory Stability in Extremely Premature Infants

The Effect of Standardizing the Definition of a Clinically Significant Cardiopulmonary Event on Length of Stay

Caffeine as Respiratory Stimulant in Preterm Infants